Nerve growth factor, clinical applications and production of the recombinant protein

M Zangi; H Ofoghi

Journal of Inflammatory Diseases

The Official Journal of Qazvin University of Medical Sciences

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Publication Malpractice Statement Reviewer and AE Registration Form Support Contact Us

Authors Guide Submit Manuscript

Nerve growth factor, clinical applications and production of the recombinant protein

Author(s):

M Zangi,

H Ofoghi^,*

Journal of Inflammatory Diseases:Vol. 20, issue 6; 70-53

Published online:Mar 31, 2017

Article type:Review Article

How to Cite:Zangi M, Ofoghi H. Nerve growth factor, clinical applications and production of the recombinant protein. J Inflamm Dis. 2024;20(6):e156002. doi:

Abstract

The mammalian neurotrophin family proteins, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4/5 (NT-4/5) are known as neuronal survival factors. NGF, one of the most important cytokines, is composed of 118 amino acids. NGF is involved in the growth and differentiation of neural cells of the vertebrate peripheral sympathetic nerve as well as basal forebrain cholinergic neurons which degenerate in Alzheimer’s disease. In addition, it is implicated in the regulation of synaptic transmission and synaptogenesis in the central nervous system. NGF is produced by a variety of immune cells, including B cells, T cells, monocytes and mast cells as well as nervous system and binds through two distinct receptors, TrkA and p75NTR which signaling through them leads to the neuronal differentiation and cell death respectively. Considering the importance of this protein as a drug, NGF has been proposed for the treatment of neuron degenerative diseases such as Alzheimer's, Parkinson's and multiple sclerosis. To produce enough protein for research and clinical applications, genetic engineering techniques are used to produce recombinant forms. To date, there are no reports about the systems for production of the recombinant human NGF in an effective, low cost, with industrial production. Plants as a safe host generally offer major advantages such as free of animal pathogens, low costs, the ability to produce a protein similar to natural protein, and industrial production in large scale. Then they are suitable for the production of recombinant human NGF.

Keywords

Nerve growth factor

Neurotrophin

Recombinant protein

Import into EndNote Import into BibTex

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 0
Last Update: 2 days ago
Scopus by Title: 0
Last Update: 2 days ago
Scopus by Title (Ref): 0
Last Update: 2 days ago
CrossRef: 0
Last Update: 2 days ago

Metrics

Purchasing Reprints

Copyright Clearance Center (CCC) handles bulk orders for article reprints for Brieflands. To place an order for reprints, please click here ( https://www.copyright.com/landing/reprintsinquiryform/ ). Clicking this link will bring you to a CCC request form where you can provide the details of your order. Once complete, please click the ‘Submit Request’ button and CCC’s Reprints Services team will generate a quote for your review.

Search Relations

Author(s):

M Zangi:[PubMed][Scholar]
H Ofoghi:[PubMed][Scholar]

The Official Journal of Qazvin University of Medical Sciences

Outlines

Nerve growth factor, clinical applications and production of the recombinant protein

Abstract

Last Update: 2 days ago

Last Update: 2 days ago

Last Update: 2 days ago

Last Update: 2 days ago